IL164643A0 - Immunogogical methods and compositions for treatment of alzheimer's disease - Google Patents
Immunogogical methods and compositions for treatment of alzheimer's diseaseInfo
- Publication number
- IL164643A0 IL164643A0 IL16464303A IL16464303A IL164643A0 IL 164643 A0 IL164643 A0 IL 164643A0 IL 16464303 A IL16464303 A IL 16464303A IL 16464303 A IL16464303 A IL 16464303A IL 164643 A0 IL164643 A0 IL 164643A0
- Authority
- IL
- Israel
- Prior art keywords
- methods
- disease
- alzheimer
- compositions
- immunogogical
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 abstract 1
- 230000003941 amyloidogenesis Effects 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37391402P | 2002-04-19 | 2002-04-19 | |
PCT/CA2003/000502 WO2003089460A1 (fr) | 2002-04-19 | 2003-04-07 | Methodes et compositions immunologiques pour le traitement de la maladie d'alzheimer |
Publications (1)
Publication Number | Publication Date |
---|---|
IL164643A0 true IL164643A0 (en) | 2005-12-18 |
Family
ID=29251102
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16464303A IL164643A0 (en) | 2002-04-19 | 2003-04-07 | Immunogogical methods and compositions for treatment of alzheimer's disease |
IL164643A IL164643A (en) | 2002-04-19 | 2004-10-17 | Peptides, immunogenic compositions containing them and use thereof for the preparation of medicaments for the treatment of alzheimer's disease |
IL196532A IL196532A (en) | 2002-04-19 | 2009-01-15 | Immunological compositions for the treatment of alzheimer's disease |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL164643A IL164643A (en) | 2002-04-19 | 2004-10-17 | Peptides, immunogenic compositions containing them and use thereof for the preparation of medicaments for the treatment of alzheimer's disease |
IL196532A IL196532A (en) | 2002-04-19 | 2009-01-15 | Immunological compositions for the treatment of alzheimer's disease |
Country Status (18)
Country | Link |
---|---|
US (5) | US20030232758A1 (fr) |
EP (2) | EP1497321B1 (fr) |
JP (3) | JP4662719B2 (fr) |
KR (1) | KR100994748B1 (fr) |
CN (1) | CN100360555C (fr) |
AT (1) | ATE514707T1 (fr) |
AU (1) | AU2003218560B2 (fr) |
CA (1) | CA2481952C (fr) |
ES (1) | ES2368907T3 (fr) |
HK (2) | HK1072947A1 (fr) |
IL (3) | IL164643A0 (fr) |
MX (1) | MXPA04010255A (fr) |
NO (2) | NO335192B1 (fr) |
NZ (1) | NZ536064A (fr) |
PL (1) | PL209696B1 (fr) |
SG (1) | SG173214A1 (fr) |
WO (1) | WO2003089460A1 (fr) |
ZA (1) | ZA200408811B (fr) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2082749A3 (fr) | 2000-07-07 | 2010-06-30 | Bioarctic Neuroscience AB | Prévention et traitement de la maladie d'Alzheimer |
CA2504349A1 (fr) * | 2001-11-02 | 2003-05-15 | Diagenics International Corporation | Methodes et compositions d'anticorps monoclonaux specifiques des proteines beta-amyloides |
US20050106626A1 (en) * | 2002-10-20 | 2005-05-19 | George Pieczenik | Ligand binding of amyloid peptide protein epitope |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
US8193250B2 (en) | 2004-10-22 | 2012-06-05 | Mount Sinai School Of Medicine | Compositions and methods for treating alzheimer's disease and related disorders and promoting a healthy nervous system |
US20090123952A1 (en) * | 2004-11-12 | 2009-05-14 | Pfizer, Inc. | Method of Measuring Amyloid-Beta Peptides |
KR101667623B1 (ko) | 2005-11-30 | 2016-10-19 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
PL1954718T3 (pl) | 2005-11-30 | 2015-04-30 | Abbvie Inc | Przeciwciała skierowane przeciwko A globulomerowi, ich reszty wiążące antygeny, odpowiednie hybrydomy, kwasy nukleinowe, wektory, komórki gospodarze, sposoby wytwarzania tych przeciwciał, kompozycje zawierające te przeciwciała, zastosowania tych przeciwciał i sposoby stosowania tych przeciwciał |
EP2808032B1 (fr) | 2005-12-12 | 2018-08-01 | AC Immune S.A. | Anticorps specifiques pour a beta possédant des propriétés thérapeutiques |
CN101421299A (zh) * | 2006-02-22 | 2009-04-29 | 株式会社林原生物化学研究所 | 用于诱导产生抗淀粉样β肽抗体的肽疫苗 |
CA2630344C (fr) | 2006-03-23 | 2015-04-28 | Bioarctic Neuroscience Ab | Anticorps ameliores selectifs de protofibrilles et leur utilisation |
JP5190957B2 (ja) * | 2006-04-28 | 2013-04-24 | 国立大学法人 鹿児島大学 | アミロイドβ線維化阻害ペプチド |
MX2009000476A (es) | 2006-07-14 | 2009-01-28 | Ac Immune Sa | Anticuerpo humanizado contra beta amiloide. |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
EP2094730A4 (fr) * | 2006-12-07 | 2010-08-04 | Mayo Foundation | Procédés et matériaux associés à des anticorps anti-amyloïdes |
IL199534A (en) | 2007-01-05 | 2013-01-31 | Univ Zuerich | An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses. |
EP2124952A2 (fr) | 2007-02-27 | 2009-12-02 | Abbott GmbH & Co. KG | Méthode de traitement d'amyloïdoses |
MX2009009234A (es) | 2007-03-01 | 2009-12-01 | Probiodrug Ag | Uso nuevo de inhibidores de ciclasa de glutaminilo. |
WO2008128985A1 (fr) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Dérivés de thio-urée utilisés comme inhibiteurs de la glutaminyl cyclase |
US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
AU2008311367B2 (en) | 2007-10-05 | 2014-11-13 | Ac Immune S.A. | Use of anti-amyloid beta antibody in ocular diseases |
WO2010024927A2 (fr) * | 2008-08-28 | 2010-03-04 | The Research Foundation Of State University Of New York | Traitement des amyloïdoses au moyen de protéines basiques de myéline ou de fragments desdites |
US8912145B2 (en) | 2008-11-28 | 2014-12-16 | Hokko Chemical Industry Co., Ltd. | Vaccine composition for prophylaxis and/or therapy of Alzheimer's disease |
WO2010061899A1 (fr) * | 2008-11-28 | 2010-06-03 | 北興化学工業株式会社 | Plante de soja transformée qui stocke un vaccin, et utilisation de celle-ci |
CN101797493B (zh) * | 2009-02-06 | 2014-05-21 | 上海抗体药物国家工程研究中心有限公司 | 一种在反应釜中制备亲和层析介质的方法 |
CN101486768B (zh) * | 2009-02-25 | 2012-05-30 | 吉林大学 | 一种用于治疗阿尔茨海默氏病的抗原蛋白及蛋白基因 |
WO2010124028A2 (fr) * | 2009-04-21 | 2010-10-28 | Vasylyev Sergiy V | Systèmes de collecte de lumière et d'éclairage à guide d'onde plan |
KR101755737B1 (ko) | 2009-09-11 | 2017-07-07 | 프로비오드룩 아게 | 글루타미닐 사이클라제의 억제제로서 헤테로사이클릭 유도체 |
US9181233B2 (en) | 2010-03-03 | 2015-11-10 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
CA2789440C (fr) | 2010-03-10 | 2020-03-24 | Probiodrug Ag | Inhibiteurs heterocycliques de la glutaminyl cyclase (qc, ec 2.3.2.5) |
MX336196B (es) | 2010-04-15 | 2016-01-11 | Abbvie Inc | Proteinas de union a amiloide beta. |
JP5945532B2 (ja) | 2010-04-21 | 2016-07-05 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 |
CA2806909C (fr) | 2010-07-30 | 2019-12-17 | Ac Immune S.A. | Anticorps humanises surs et fonctionnels |
MX358739B (es) | 2010-08-14 | 2018-09-03 | Abbvie Inc Star | Proteinas de union a amiloide beta. |
US20120321694A1 (en) * | 2010-10-27 | 2012-12-20 | Daniel Larocque | Compositions and uses |
ES2570167T3 (es) | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Derivados de benzimidazol como inhibidores de glutaminil ciclasa |
DE102011057019A1 (de) * | 2011-12-23 | 2013-06-27 | Forschungszentrum Jülich GmbH | Standard zur Quantifizierung von pathogenen Aggregaten aus körpereigenen Proteinen |
JP6130401B2 (ja) * | 2012-01-20 | 2017-05-17 | アンナプラガダ,アナンス | 医学画像を客観的に特徴付けるための方法および組成物 |
US9534048B2 (en) * | 2012-08-24 | 2017-01-03 | University Health Network | Antibodies to TTR and methods of use |
PL2895512T3 (pl) * | 2012-09-12 | 2018-11-30 | Neurimmune Holding Ag | Przeciwciała swoiste dla polipeptydu amyloidowego ludzkich wysepek (HIAPP) i ich zastosowania |
HUE051127T2 (hu) * | 2012-10-15 | 2021-03-01 | Medimmune Ltd | Béta-amiloid antitestek |
WO2015017280A1 (fr) | 2013-07-28 | 2015-02-05 | Qantu Therapeutics, Inc. | Formulation de vaccins induisant une réponse immunitaire de type th2 |
FI3137094T3 (fi) | 2014-04-29 | 2023-03-20 | Advantage Therapeutics Inc | Alzheimerin taudin (ad) hoitaminen ja ehkäiseminen |
SG11201610734RA (en) | 2014-07-10 | 2017-01-27 | Bioarctic Neuroscience Ab | IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES |
MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
WO2017098516A1 (fr) * | 2015-12-10 | 2017-06-15 | The National Institute for Biotechnology in the Negev Ltd. | Variantes du domaine inhibiteur du précurseur de la bêta-protéine amyloïde |
ES2848720T3 (es) * | 2016-11-25 | 2021-08-11 | Genuv Inc | Composición para promover la diferenciación y la protección de células madre neurales y método para inducir la regeneración neural utilizando la misma |
MA49947B1 (fr) | 2017-08-22 | 2023-03-31 | Biogen Ma Inc | Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes |
ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
US11958889B2 (en) | 2017-10-25 | 2024-04-16 | Janssen Pharmaceuticals, Inc. | Compositions of phosphorylated tau peptides and uses thereof |
CA3099946A1 (fr) * | 2018-05-18 | 2019-11-21 | Universite Laval | Utilisation d'un agoniste de nod2 pour le traitement, la prophylaxie et/ou le retardement de l'apparition de la sclerose en plaques et de la maladie d'alzheimer |
WO2020163730A2 (fr) * | 2019-02-08 | 2020-08-13 | Ac Immune S.A. | Méthode d'administration sûre d'un vaccin de peptide de tau phosphorylé |
KR20220005033A (ko) | 2019-04-24 | 2022-01-12 | 얀센 파마슈티칼즈, 인코포레이티드 | 타우 백신의 이종 투여 |
TW202144387A (zh) * | 2020-02-11 | 2021-12-01 | 美商聯合生物醫學公司 | 針對胰島澱粉樣多肽(iapp)的胜肽免疫原及其預防和治療與聚集iapp相關疾病的製劑 |
CN115925987A (zh) * | 2022-02-28 | 2023-04-07 | 安域生物科技(杭州)有限公司 | 基于β-淀粉样蛋白修饰的抗原多肽及其应用 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4666829A (en) * | 1985-05-15 | 1987-05-19 | University Of California | Polypeptide marker for Alzheimer's disease and its use for diagnosis |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
DK0671948T3 (da) | 1992-06-25 | 1997-09-01 | Smithkline Beecham Biolog | Vaccinepræparat indeholdende adjuvanser |
US5766846A (en) * | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
US5840294A (en) | 1993-03-29 | 1998-11-24 | Queen's University At Kingston | Method for treating amyloidosis |
US5759551A (en) | 1993-04-27 | 1998-06-02 | United Biomedical, Inc. | Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines |
CA2161445C (fr) * | 1993-04-27 | 2009-06-30 | Anna Efim Ladd | Peptides de lhrh immunogenes et stimulateurs universels synthetiques de l'immunite pour les vaccins |
US5744144A (en) | 1993-07-30 | 1998-04-28 | University Of Pittsburgh University Patent Committee Policy And Procedures | Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
CA2242851A1 (fr) | 1995-08-17 | 1997-02-27 | The Ontario Cancer Institute | Methode de controle de l'assemblage des fibrilles de proteine |
US6750324B1 (en) * | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
WO2001097607A2 (fr) | 2000-06-20 | 2001-12-27 | The Governing Council Of The University Of Toronto | Modele d'animal transgenique presentant des troubles de neurodegenerescence |
US6310810B1 (en) | 2000-07-14 | 2001-10-30 | Raj Kumar Jain | High-speed sense amplifier |
US6906169B2 (en) * | 2001-05-25 | 2005-06-14 | United Biomedical, Inc. | Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide |
-
2003
- 2003-04-07 WO PCT/CA2003/000502 patent/WO2003089460A1/fr active Application Filing
- 2003-04-07 KR KR1020047016794A patent/KR100994748B1/ko not_active IP Right Cessation
- 2003-04-07 EP EP03711746A patent/EP1497321B1/fr not_active Expired - Lifetime
- 2003-04-07 NZ NZ536064A patent/NZ536064A/en not_active IP Right Cessation
- 2003-04-07 ES ES03711746T patent/ES2368907T3/es not_active Expired - Lifetime
- 2003-04-07 JP JP2003586180A patent/JP4662719B2/ja not_active Expired - Fee Related
- 2003-04-07 EP EP10182139.5A patent/EP2330113B1/fr not_active Expired - Lifetime
- 2003-04-07 AT AT03711746T patent/ATE514707T1/de not_active IP Right Cessation
- 2003-04-07 MX MXPA04010255A patent/MXPA04010255A/es unknown
- 2003-04-07 CA CA2481952A patent/CA2481952C/fr not_active Expired - Fee Related
- 2003-04-07 IL IL16464303A patent/IL164643A0/xx unknown
- 2003-04-07 CN CNB038088584A patent/CN100360555C/zh not_active Expired - Fee Related
- 2003-04-07 AU AU2003218560A patent/AU2003218560B2/en not_active Ceased
- 2003-04-07 SG SG2006073324A patent/SG173214A1/en unknown
- 2003-04-07 PL PL373450A patent/PL209696B1/pl unknown
- 2003-04-10 US US10/411,544 patent/US20030232758A1/en not_active Abandoned
-
2004
- 2004-10-17 IL IL164643A patent/IL164643A/en not_active IP Right Cessation
- 2004-11-01 ZA ZA2004/08811A patent/ZA200408811B/en unknown
- 2004-11-18 NO NO20045021A patent/NO335192B1/no not_active IP Right Cessation
-
2005
- 2005-07-08 HK HK05105780.8A patent/HK1072947A1/xx not_active IP Right Cessation
- 2005-07-08 HK HK11113133.8A patent/HK1158665A1/zh not_active IP Right Cessation
- 2005-07-13 US US11/180,225 patent/US20090041771A1/en not_active Abandoned
-
2009
- 2009-01-15 IL IL196532A patent/IL196532A/en not_active IP Right Cessation
- 2009-10-30 JP JP2009251464A patent/JP5345920B2/ja not_active Expired - Fee Related
-
2012
- 2012-03-29 US US13/434,205 patent/US20120315321A1/en not_active Abandoned
- 2012-11-13 JP JP2012249078A patent/JP2013075898A/ja not_active Withdrawn
-
2013
- 2013-11-07 NO NO20131483A patent/NO20131483L/no not_active Application Discontinuation
-
2014
- 2014-04-07 US US14/246,830 patent/US20140212481A1/en not_active Abandoned
-
2016
- 2016-06-17 US US15/186,049 patent/US20160297876A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL164643A0 (en) | Immunogogical methods and compositions for treatment of alzheimer's disease | |
MXPA05003621A (es) | Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos. | |
BG104562A (en) | Composition and method for prevention and treatment of amyloidogenic disease | |
TWI263503B (en) | Composition comprising an antibody or a polypeptide preparation as the active agent for the prevention and treatment of amyloidogenic disease and method for in vitro screening of the antibody | |
MXPA05008156A (es) | Inmunizacion activa para generar anticuerpos para beta-a soluble. | |
ATE535252T1 (de) | Peptid-konjugat-zusammensetzungen und -verfahren zur prävention und behandlung von alzheimer- krankheit | |
WO2002046222A3 (fr) | Compositions et procede de diagnostic de la maladie d'alzheimer | |
HUP0204074A2 (hu) | Abéta peptidet kiválasztó humanizált ellenanyagok | |
TW200617023A (en) | Antibodies directed against amyloid-beta peptide and methods using same | |
WO2005018424A3 (fr) | Anticorps specifiques de la proteine amyloide fibrillaire et procedure permettant de detecter des depots de proteines amyloides fibrillaires | |
HK1101131A1 (en) | Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients | |
MXPA04000334A (es) | Compuestos de alquilamida n-(3-amino-2-hidroxi-propil) substituidos. | |
ZA200308767B (en) | Immunogenic peptide composition for the prevention and treatment of alzheimers disease | |
GB2364059A (en) | Beta-Secretase enzyme compositions and methods | |
TW200732348A (en) | Monoclonal antibody | |
MXPA04000338A (es) | Diamindioles para tratamiento de enfermedad de alzheimer. | |
MXPA05010914A (es) | Metodo de tratamiento de la enfermedad de alzheimer. | |
MXPA04002785A (es) | Aminas sustituidas para tratamiento de enfermedad de alzheimer. | |
MXPA03011521A (es) | Aminadioles para tratamiento de enfermedad de alzheimer. | |
DE60210614D1 (de) | Für die behandlung von alzheimer krankheit geeignete makrocyclen | |
DK1553985T3 (da) | Biphenyler som billeddannelsesmiddel i forbindelse med Alzheimers sygdom | |
MXPA03011502A (es) | Aminoalcoholes sustituidos utiles en tratamiento de enfermedad de alzheimer. | |
MXPA04000337A (es) | Amindioles para tratamiento de enfermedad de alzheimer. | |
RU2353389C2 (ru) | Способы лечения болезни альцгеймера с использованием антител, направленных против пептида амилоида-бета, и их композиций | |
WO2002102849A3 (fr) | Nouvelle proteine associee au cancer |